Takeda Pharmaceutical Company Limited
TAKFinancial Statements
Income Statement (Annual)
Amounts in millions
2025
3/31/2025
Revenue
30,696
Cost of Revenue
10,587
Gross Profit
20,109
Gross Margin
65.5%
Operating Income
2,295
Operating Margin
7.5%
Net Income
723
Net Margin
2.4%
EPS (Basic)
$34.17
EPS (Diluted)
$33.62
EBITDA
8,110
EBITDA Margin
26.4%
2024
3/31/2024
Revenue
28,567
Cost of Revenue
9,591
Gross Profit
18,976
Gross Margin
66.4%
Operating Income
1,434
Operating Margin
5.0%
Net Income
965
Net Margin
3.4%
EPS (Basic)
$46.05
EPS (Diluted)
$45.58
EBITDA
7,664
EBITDA Margin
26.8%
2023
3/31/2023
Revenue
26,984
Cost of Revenue
8,335
Gross Profit
18,649
Gross Margin
69.1%
Operating Income
3,286
Operating Margin
12.2%
Net Income
2,124
Net Margin
7.9%
EPS (Basic)
$102.15
EPS (Diluted)
$100.97
EBITDA
8,603
EBITDA Margin
31.9%
2022
3/31/2022
Revenue
23,912
Cost of Revenue
7,416
Gross Profit
16,496
Gross Margin
69.0%
Operating Income
3,088
Operating Margin
12.9%
Net Income
1,541
Net Margin
6.4%
EPS (Basic)
$73.57
EPS (Diluted)
$72.94
EBITDA
7,928
EBITDA Margin
33.2%
2021
3/31/2021
Revenue
21,425
Cost of Revenue
6,662
Gross Profit
14,763
Gross Margin
68.9%
Operating Income
3,412
Operating Margin
15.9%
Net Income
2,519
Net Margin
11.8%
EPS (Basic)
$120.36
EPS (Diluted)
$119.48
EBITDA
6,591
EBITDA Margin
30.8%